Results 211 to 220 of about 44,303 (310)

Main factors associated with variability in the assessment of the objective response rate. A re‐analysis of the PHEREXA phase 3 clinical trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Local investigators (LIs) overestimate the objective response rate (ORR) in comparison to Blinded Independent Central Reviewers (BICR) in oncology. In this study, we re‐analysed data obtained in the PHEREXA trial (NCT01026142) with the following aims: i) to confirm at the single‐patient level the discrepancy observed by analysing ...
Gennaro Daniele   +3 more
wiley   +1 more source

Macrophage‐targeted cerium‐tannic acid metal‐polyphenol framework nanoenzyme promotes in situ heart valves regeneration through adaptive immunomodulation

open access: yesBMEMat, EarlyView.
A novel nanoenzyme based on cerium ions‐tannic acid metal‐polyphenol framework (FCT) has been developed and loaded onto DHVs for targeting M1 macrophages to reduce their ROS level and reprogram macrophage phenotype, thereby eliminating inflammation, promoting endothelialization and adaptive matrix remodeling of scaffolds, offering a promising strategy ...
Peng Song   +9 more
wiley   +1 more source

2D copper nanozyme patches facilitate bone regeneration via interfacial modulation of osteoclast‐osteoblast dynamics

open access: yesBMEMat, EarlyView.
This study develops a nano‐enzyme patch (ezPatch) targeting bone interfaces. Utilizing ligand‐to‐metal charge transfer (LMCT) catalysis and bone‐targeting ligands on copper nanosheets, ezPatch simultaneously scavenges reactive oxygen species (ROS) and generates oxygen in situ at bone‐losing sites.
Yi Chen   +12 more
wiley   +1 more source

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

open access: yesBMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai   +14 more
wiley   +1 more source

A nanoplatform that induces dual‐amino acid deprivation to reverse tumor immunosuppression and enhance metabolic immunotherapy

open access: yesBMEMat, EarlyView.
ZIF‐8‐based nanoparticles co‐delivering CB‐839 (glutaminase inhibitor) and 1‐MT (IDO1 inhibitor), dual‐targeting glutamine/tryptophan metabolism to induce immunogenic cell death, activate STING, block kynurenine production, reverse immunosuppression, and enhance cancer immunotherapy to suppress primary/distant tumors.
Wenli Ning   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy